Scholar Rock Holding Corporation (SRRK) 股票分析

公司概述

Scholar Rock Holding Corporation is a biopharmaceutical entity dedicated to enhancing the quality of life for patients suffering from spinal muscular atrophy (SMA) and other rare, severe neuromuscular diseases. Operating within the healthcare sector specifically under the biotechnology industry classification, the company leverages novel insights into molecular mechanisms involving growth factor activation to develop targeted therapies. The enterprise currently commands a market capitalization of $5.74 billion and employs a workforce of 289 individuals to execute its research and development initiatives. While specific annual revenue figures are not disclosed in the available data, the substantial market capitalization suggests that the market assigns significant value to the company's pipeline assets and its strategic focus on high-need therapeutic areas, positioning it as a notable player in the rare disease landscape despite the lack of traditional revenue reporting in the current period.

财务健康

The company reported a net income of $-377,939,008 over the trailing twelve months, accompanied by an EBITDA of $-382,987,008, while the revenue figure for the trailing twelve months is not available in the provided dataset. The substantial gap between the reported net income and the available revenue data indicates a cost structure where expenses, likely driven by clinical trial costs and R&D investments, significantly outpace recognized sales in the current accounting period. Free cash flow stands at $-162,622,256, reflecting a period of capital deployment rather than cash generation, which implies limited financial flexibility for immediate dividend payments or large-scale shareholder buybacks at this juncture. The gross margin, operating margin, and profit margin are all recorded at 0.0%, a metric typical for early-stage biotechnology firms where revenues are negligible or not yet recognized against high operational expenditures. On the liability side, the company holds $367.56 million in cash against $108.92 million in debt, resulting in a debt-to-equity ratio of 44.37, which suggests a balance sheet that is relatively un-leveraged and conservatively managed despite the negative earnings. The current ratio of 6.95 indicates robust short-term liquidity, demonstrating that the company possesses sufficient current assets to cover its current liabilities many times over. Furthermore, the return on equity is -123.1% and the return on assets is -54.7%, metrics that reveal that management is currently utilizing shareholder capital and assets to fund growth initiatives rather than generating immediate returns, a common characteristic in the biotechnology development phase.

估值评估

The trailing twelve-month P/E ratio is not available due to the lack of earnings, whereas the forward P/E ratio is recorded at -23.30, implying that the market is pricing the stock based on anticipated future profitability rather than historical performance. The price-to-book ratio stands at 22.09, indicating that the market values the company's equity at a significant premium over its book value, likely reflecting the intangible value of its intellectual property and drug pipeline. Alternative valuation metrics such as the price-to-sales ratio are not available, and the EV/EBITDA ratio is -14.32, suggesting that traditional multiple-based comparisons are not applicable given the company's current cash burn and lack of sales. The stock has traded between a 52-week low of $22.71 and a 52-week high of $51.62; without a specific current price provided in the facts, the valuation context relies on these historical trading bounds to assess relative volatility and positioning. The beta value is 0.69, indicating that the stock's price volatility is lower than the broader market, suggesting that the stock price is less sensitive to general market fluctuations compared to high-beta equities.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A in the available facts, preventing a direct comparison of growth rates between revenue expansion and earnings performance for this specific reporting period. As the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available cash and earnings are effectively retained and reinvested back into the company to fund ongoing research and development efforts. The absence of a dividend payout ratio confirms that the company's capital allocation strategy prioritizes organic growth and pipeline advancement over returning capital to shareholders in the form of income distributions. Consequently, the overall growth and income profile for Scholar Rock Holding Corporation is characterized by a focus on long-term value creation through product development rather than current income generation or dividend stability.